PYC Therapeutics (ASX: PYC) — Perfil da empresa, notícias e dados financeiros
PYC Therapeutics develops RNA therapeutics for genetic diseases, with a focus on precision medicines addressing underlying causes.
PYC Therapeutics
PYC Therapeutics is a clinical-stage biotechnology company that develops novel RNA therapeutics using a proprietary cell-penetrating peptide drug delivery platform to treat severe genetic diseases. The company combines scientific research, clinical insights, and targeted drug delivery technology to address monogenic conditions with limited or no existing treatment options. Its pipeline focuses on precision RNA therapies for inherited ocular and renal conditions, including retinitis pigmentosa type 11, autosomal dominant optic atrophy, and autosomal dominant polycystic kidney disease. Headquartered in Australia, the company conducts preclinical and clinical development programs designed to restore normal protein expression and modify disease progression in targeted patient populations.
Resumo
Operações
Produtos e/ou serviços de PYC Therapeutics
- Cell-Penetrating Peptide Drug Delivery Platform: Proprietary drug delivery technology utilizing cell-penetrating peptides conjugated to RNA therapeutics to enable intracellular delivery across cell membranes, overcoming structural barriers to enhance therapeutic potency inside targeted cells for severe monogenic diseases.
- Retinitis Pigmentosa Type 11 Therapeutics: Clinical-stage RNA investigational therapy targeting haploinsufficiency caused by PRPF31 gene mutations, designed to restore functional protein production inside retinal cells and halt progressive vision loss in affected ophthalmic patients globally.
- Autosomal Dominant Optic Atrophy Therapeutics: Investigational precision RNA therapeutic program addressing optic nerve atrophy driven by OPA1 gene mutations, aiming to boost functional OPA1 protein expression and preserve retinal ganglion cell structure and vision.
- Autosomal Dominant Polycystic Kidney Disease Therapeutics: Targeted RNA drug candidate designed to increase polycystin-1 protein expression by modulating PKD1 gene output, aiming to reduce cyst growth and preserve long-term kidney function in patients with polycystic kidney disease.
- Phelan-McDermid Syndrome Therapeutics: Preclinical RNA therapeutic candidate targeting SHANK3 gene haploinsufficiency, formulated with cell-penetrating peptides to deliver functional protein-restoring oligomers into central nervous system tissues for treating neurodevelopmental genetic impairment.
- Monogenic Disease Research and Clinical Development: Translational biotechnology operations including preclinical screening, non-human primate pharmacology studies, and multi-center clinical trials evaluating peptide-conjugated oligonucleotide therapeutics across targeted genetic indications in ophthalmology, nephrology, and neurology.
equipe executiva do PYC Therapeutics
- Rohan HockingsCEO & Executive Director
- Thomas UlmerChief Financial Officer
- Janya GrainokChief Scientific Officer
- Jonathan RileyGeneral Counsel & Joint Company Secretary
- Paula CunninghamChief Development Officer
- Candice JungeChief Clinical Development Officer
- Stephen Alan LedgerJoint Company Secretary
Comunicados recentes
O que a PYC Therapeutics (PYC) comunicou ao mercado, do mais recente para o mais antigo.
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - PYC
- Notification of cessation of securities - PYC
- PKD Program - Presentation of Data at ASN ConferenceFato relevante
- RP11 PROGRAM - PRESENTATION AT EURETINA 2026
- Notification of cessation of securities - PYC
- Becoming a substantial holder
Principais indicadores financeiros
Resultados divulgados pela PYC Therapeutics, em AUD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 26 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -166.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -82,7 mi | -43,3 mi | |
| 23,5 mi | -53,6 mi | -50,3 mi | |
| 22,1 mi | -38,9 mi | -37,7 mi | |
| 15,8 mi | -39,2 mi | -22,8 mi |